 This phase IIA trial studies how well a recombinant human papillomavirus nonavalent works in preventing human papilloma virus HPV in younger healthy participants. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last a long time and cause cancers of the cervix, vagina, vulva, anus or oropharynx over many years among adults. Recombinant human papillomavirus nonavalent vaccine is a type of nonavalent vaccine a vaccine that works against nine different viruses or other microorganisms and may protect against HPV infection and the health problems that HPV infection can cause. 